S&P 500 Healthcare Sector SEC Filings — October 20, 2026

Q3 2026 revenue up 22% YoY to $3.05B from $2.51B, worldwide procedures up ~15%, da Vinci placements rose to 546 from 427, non-GAAP EPS $3.00 vs $2.40

FY2026 guidance calls for da Vinci procedure growth of 14%-15% with management expecting the midpoint, reaffirming demand durability

GAAP net income fell to $523M ($1.49/share) from $704M ($1.95) and GAAP operating income declined to $593M from $760M, a GAAP margin compression that masks underlying growth

The $22M net-of-tax ($0.06/share) IEEPA tariff refund inflated Q3 results; excluding it, the underlying beat is smaller than headline figures imply

FY2026 non-GAAP gross margin guided to 68.7%-69.3% including a 0.9% tariff drag, with non-GAAP opex growth of 11%-13%, implying operating leverage is contingent on cost discipline

Director Alvarez Ralph received 10.0107 shares at $1,240.34 (~$12.4K), bringing holdings to 55,848.2299 shares; routine director compensation with no open-market purchase or sale

Director Fyrwald J Erik holds 75,544.1259 shares after a 7.9951-share award (~$9.92K); the largest holder among the four directors, a mild alignment signal

Director LUCIANO JUAN R holds 16,969.6463 shares after a 12.8325-share award (~$15.9K); the award size was the largest among the four directors

Director Sulzberger Gabrielle holds 3,016.4449 shares after a 3.9976-share award (~$4.96K), the smallest holding in the group

Board expanded to eleven members with Daniel Brennan (former Boston Scientific EVP/CFO), who joined the Audit and Finance Committee and received a $400,000 RSU award vesting October 2027, adding financial-oversight depth

$450M antitrust class action settlement charge drove the GAAP net income decline; further legal reserves or related claims could pressure reported earnings in coming quarters

GAAP operating income fell to $593M from $760M despite 22% revenue growth, indicating a widening gap between GAAP and non-GAAP profitability

One-time tariff refund ($0.06/share) flattered both GAAP and non-GAAP results; the non-recurring nature means sequential comparisons may disappoint

FY2026 guidance includes a 0.9% gross margin tariff impact; continued trade policy volatility could pressure the 68.7%-69.3% non-GAAP gross margin range

Non-GAAP opex growth guided at 11%-13%, which, if revenue growth decelerates toward the 14%-15% procedure range, could erode operating leverage

Board appointment disclosed with no related-party transactions; the filing is neutral, but Brennan's concurrent seats at Waters and Madrigal warrant monitoring for interlocking-directorate or conflict considerations

All four Form 4s reflect uniform award pricing at $1,240.34 and no open-market purchases by directors; the absence of discretionary buying reduces the insider-conviction signal

Worldwide procedures up ~15% with 14%-15% FY2026 guidance and placements up 28% YoY (546 vs 427); the installed-base expansion supports recurring procedure revenue

Non-GAAP EPS of $3.00 vs $2.40 (+25% YoY) once the $0.06 tariff benefit and $450M settlement are excluded implies a cleaner underlying growth trajectory worth modeling for re-rating

da Vinci placements up ~28% YoY to 546 signal capital equipment demand strength, a leading indicator for future procedure volume

Guided non-GAAP gross margin of 68.7%-69.3% despite tariff headwinds shows pricing and mix resilience in the core franchise

Addition of a former Boston Scientific CFO to the Audit and Finance Committee strengthens capital-allocation and controls expertise ahead of a potentially active pipeline and commercial phase

Director holdings range from ~3,000 to ~75,500 shares, with ongoing equity awards gradually compounding stakes; a supportive long-term alignment backdrop for a large-cap pharma name

Intuitive Surgical's ~15% worldwide procedure growth and 14%-15% FY2026 guidance point to robust surgical robotics adoption, with placements up ~28% YoY supporting a multi-year recurring revenue runway

Intuitive's GAAP EPS fell ~24% ($1.49 vs $1.95) while non-GAAP EPS rose 25%, illustrating how litigation charges and one-time tariff refunds widen the gap; investors should reconcile adjusted figures carefully across the sector

The 0.9% gross margin tariff impact embedded in Intuitive's guidance, combined with IEEPA refund benefits in the quarter, shows trade policy is actively moving reported margins for healthcare device makers

The $450M antitrust settlement at Intuitive highlights ongoing legal exposure in large-cap healthcare; accrual timing can materially distort single-quarter GAAP comparisons

Vertex's addition of a former large-cap medtech CFO to the audit committee reflects a broader healthcare governance trend toward finance-experienced independent directors

Four Eli Lilly director awards at an identical $1,240.34 price indicate standardized annual board equity grants; no clustered insider selling was observed, consistent with a neutral insider posture across the sample

Watch whether procedure growth holds within the 14%-15% guidance range and whether non-GAAP opex growth stays within 11%-13%; date not specified in filing

Monitor for additional settlement reserves, appeals, or follow-on class actions that could affect future GAAP earnings; timing not specified in filing

Track IEEPA refund flows and any changes to tariff policy that could move the 0.9% gross margin impact assumption

Watch the Audit and Finance Committee's early actions under Brennan's tenure and any further board changes following the expansion to eleven directors

The $400,000 award vests October 2027; monitor for any Brennan open-market transactions as a signal of personal conviction

Continue tracking director holdings for any open-market purchases or sales that would depart from the uniform award pattern seen in this batch